For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
-
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
-
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
-
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
-
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
-
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
-
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
-
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
-
BUSINESS Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
-
ORGANIZATION No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
-
BUSINESS Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
-
ORGANIZATION JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
-
REGULATORY Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
-
REGULATORY CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
-
BUSINESS Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
-
BUSINESS Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
-
BUSINESS Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
-
REGULATORY CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
-
ORGANIZATION Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
-
ORGANIZATION Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…